A global effort to limit junk food marketing could have a major impact on childhood obesity
And while regaining weight is likely, its not guaranteed
Completion dates range from 2024 through 2029
Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
Chinese-developed therapeutics are reaching clinical milestones that rival Western incumbents, and the companies behind them are increasingly looking outward
General evidence for probiotics in gastrointestinal symptom management shows mixed results
